VYNE Therapeutics
Open
$0.66
Prev. Close
$0.66
High
$0.66
Low
$0.65
Market Snapshot
$21.61M
-1.0
-0.94
$501K
10
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 10 full-time employees. The company went IPO on 2018-01-25. The company is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 10 full-time employees. The company went IPO on 2018-01-25. The company is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.
Recently from Cashu
VYNE Therapeutics: Key Updates and Developments in Recent Performance and Future Outlook.
Please provide the text you would like me to summarize, and I'll create a 300-word paragraph for you.
VYNE Therapeutics: Key Developments and Stock Performance Update
Please provide the content you would like summarized, and I'll be happy to assist you.